Tumefactive demyelinating lesions during etanercept treatment requiring decompressive hemicraniectomy

被引：8

作者：

Cereda, C. W. ^{[1
]}

Zecca, C. ^{[1
]}

Mazzucchelli, L. ^{[1
]}

Valci, L. ^{[1
]}

Staedler, C. ^{[1
]}

Bassetti, C. L. ^{[1
]}

Gobbi, C. ^{[1
]}

机构：

[1] Neurol Inselspital Bern, Bern, Switzerland

来源：

MULTIPLE SCLEROSIS JOURNAL | 2013年 / 19卷 / 06期

关键词：

CNS demyelinating disease; Marburg's variant; multiple sclerosis; etanercept; ACUTE DISSEMINATED ENCEPHALOMYELITIS;

D O I：

10.1177/1352458512461969

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Tumor necrosis factor alpha (TNF-alpha) is a pro-inflammatory and immunoregulatory cytokine involved in the pathogenesis of several autoimmune disorders. Etanercept, a TNF-alpha antagonist (anti-TNF-alpha) acting as a soluble TNF-alpha receptor, has been associated with neurological demyelinating disorders. This paper aims to report an unusual case showing tumefactive central nervous system (CNS) inflammatory demyelination in a patient in the course of TNF -alpha antagonist therapy, requiring decompressive hemicraniectomy. This report is based on magnetic resonance imaging (MRI) findings and histology. A biopsy confirmed the inflammatory demyelinating nature of the lesions. The clinical presentation is unusual due to the severity of the disease process, requiring decompressive hemicraniotomy with a clinically favorable outcome.

引用

页码：820 / 823

页数：4

共 10 条

[1] Decompressive Craniectomy for Acute Disseminated Encephalomyelitis [J].